JPH05505823A - 細胞成長抑制法およびそれに有用な組成物 - Google Patents

細胞成長抑制法およびそれに有用な組成物

Info

Publication number
JPH05505823A
JPH05505823A JP91507366A JP50736691A JPH05505823A JP H05505823 A JPH05505823 A JP H05505823A JP 91507366 A JP91507366 A JP 91507366A JP 50736691 A JP50736691 A JP 50736691A JP H05505823 A JPH05505823 A JP H05505823A
Authority
JP
Japan
Prior art keywords
antibodies
antibody
cells
combination
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91507366A
Other languages
English (en)
Japanese (ja)
Inventor
トローブリッジ，イアン・スチュアート
ティートル，レイモンド
ホワイト，シュハイラ・ナホール
Original Assignee
ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ, ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア filed Critical ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ
Publication of JPH05505823A publication Critical patent/JPH05505823A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
JP91507366A 1990-03-27 1991-03-26 細胞成長抑制法およびそれに有用な組成物 Pending JPH05505823A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50003590A 1990-03-27 1990-03-27
US500,035 1990-03-27
PCT/US1991/002031 WO1991014452A1 (fr) 1990-03-27 1991-03-26 Procede pour inhiber la croissance des cellules et des compositions utiles a ce procede

Publications (1)

Publication Number Publication Date
JPH05505823A true JPH05505823A (ja) 1993-08-26

Family

ID=23987769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91507366A Pending JPH05505823A (ja) 1990-03-27 1991-03-26 細胞成長抑制法およびそれに有用な組成物

Country Status (8)

Country Link
US (1) US5667781A (fr)
EP (1) EP0525005B1 (fr)
JP (1) JPH05505823A (fr)
AT (1) ATE154245T1 (fr)
AU (1) AU642014B2 (fr)
CA (1) CA2081368A1 (fr)
DE (1) DE69126526T2 (fr)
WO (1) WO1991014452A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516887A (ja) * 2009-02-05 2012-07-26 オンコックス・エッセ・エッレ・エッレ 抗ｔｒｏｐ−２モノクローナル抗体ならびに腫瘍の治療および診断におけるその使用
JP2018024615A (ja) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE204478T1 (de) * 1993-05-03 2001-09-15 Genentech Inc Inhibierung von leukozytenadhäsion
US5922346A (en) * 1997-12-01 1999-07-13 Thione International, Inc. Antioxidant preparation
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (fr) * 2000-12-13 2002-06-13 John R. Coleman Molecules d'acide nucleique et polypeptides pour le catabolisme de l'acide abscisique
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7592143B2 (en) * 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US6977720B2 (en) * 2003-08-05 2005-12-20 Agilent Technologies, Inc. Characterization of active and passive optical properties of an optical device
WO2005094364A2 (fr) * 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Proteine d'anticorps iga utilisee en tant que medicament cytotoxique
WO2005111082A1 (fr) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps anti-tfr
EP1765868B1 (fr) * 2004-06-07 2016-04-20 MacroGenics, Inc. Anticorps contre le récepteur de transferrine
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
DK2364366T3 (da) 2008-11-05 2014-03-31 Morphosys Ag Affoldningsmetode
ES2670588T3 (es) 2009-06-26 2018-05-31 Soricimed Biopharma Inc. Péptidos derivados de soricidina y métodos para la detección de cánceres TRPV-6 y administración de fármacos
WO2011130164A2 (fr) * 2010-04-13 2011-10-20 The Regents Of The University Of California Anticorps anti-tfr non conjugués et compositions de ceux-ci pour le traitement de cancers
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
CN103534272B (zh) 2011-05-09 2016-05-11 株式会社英仙蛋白质科学 能够特异性识别转铁蛋白受体的抗体
CN102827813B (zh) * 2012-09-30 2014-12-31 苏州大学 抗人cd133单克隆抗体及其制备和应用
ES2689782T3 (es) 2012-11-08 2018-11-15 University Of Miyazaki Anticuerpo capaz de reconocer específicamente un receptor de transferrina
US9499628B2 (en) * 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
WO2023015234A1 (fr) * 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Procédés de culture cellulaire pour la production de protéines thérapeutiques
TW202328187A (zh) 2021-09-01 2023-07-16 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4925922A (en) * 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516887A (ja) * 2009-02-05 2012-07-26 オンコックス・エッセ・エッレ・エッレ 抗ｔｒｏｐ−２モノクローナル抗体ならびに腫瘍の治療および診断におけるその使用
JP2018024615A (ja) * 2016-08-10 2018-02-15 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物

Also Published As

Publication number Publication date
EP0525005A1 (fr) 1993-02-03
US5667781A (en) 1997-09-16
CA2081368A1 (fr) 1991-09-28
AU7667091A (en) 1991-10-21
ATE154245T1 (de) 1997-06-15
DE69126526D1 (de) 1997-07-17
WO1991014452A1 (fr) 1991-10-03
AU642014B2 (en) 1993-10-07
DE69126526T2 (de) 1998-02-05
EP0525005A4 (en) 1993-06-16
EP0525005B1 (fr) 1997-06-11

Similar Documents

Publication Publication Date Title
JPH05505823A (ja) 細胞成長抑制法およびそれに有用な組成物
JP3600617B2 (ja) ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤
EP0764030B1 (fr) Composition contenant d'autoanticorps pour la therapie et la prophylaxie antitumorale
CA1341082C (fr) Procede de traitement de tumeurs par inhibition fonctionnelle du recepteur du facteur de croissance cellulaire
EP0578774B1 (fr) Anticorps monoclonaux de recepteurs de facteurs de cellules souches
KR100620554B1 (ko) Ｔａｇ-72에 대한 인간화 항체
TWI400087B (zh) 抗-整合蛋白免疫接合體，方法及用途
JP2001521520A (ja) 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
JP2019047807A (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
EA026990B1 (ru) Антитела, связывающиеся с человеческой клеткой dec-205
JPH09508390A (ja) 免疫刺激性モノクローナル抗体
TW200817437A (en) Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
US20220332829A1 (en) Anti-b7-h3 antibody and application thereof
WO2011137687A1 (fr) Anticorps dirigé contre l'antigène carcino-embryonnaire et ses utilisations
US11814441B2 (en) Bi-specific antigen-binding polypeptides
US7344715B2 (en) Method for treating multiple myeloma
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
RU2127122C1 (ru) Композиция, обладающая цитотоксическим действием, способ обработки лейкозной клетки in vitro
Pietersz et al. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy
JP2000509015A (ja) Ｔ細胞及びｂ細胞リンパ腫及び白血病の治療のためのｃｄ４８に対する抗体の使用
EP4209512A1 (fr) Développement d'un agent thérapeutique contenant un adaptateur et son utilisation
CN114874330B (zh) 靶向单链抗体的中和性单克隆抗体
WO2018233333A1 (fr) Anticorps monoclonal de cellules souches humaine ciblées et application d'un anticorps monoclonal